Literature DB >> 34498111

[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.

Simone Krebs1,2, Christian Grommes3, Michael R McDevitt1,2, Sean D Carlin4, Joseph A O'Donoghue5, Maya S Graham3, Robert J Young6, Heiko Schöder1,2, Philip H Gutin7, Neil H Bander8, Joseph R Osborne9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34498111     DOI： 10.1007/s00259-021-05543-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  Clin Cancer Res       Date:  2015-07-14       Impact factor: 12.531

2.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-21       Impact factor: 9.236

3.  Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Authors:  A Gabriella Wernicke; Mark A Edgar; Ehud Lavi; He Liu; Pamela Salerno; Neil H Bander; Philip H Gutin
Journal:  Arch Pathol Lab Med       Date:  2011-11       Impact factor: 5.534

4.  PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.

Authors:  Adrien Holzgreve; Annamaria Biczok; Viktoria C Ruf; Friederike Liesche-Starnecker; Katja Steiger; Maximilian A Kirchner; Marcus Unterrainer; Lena Mittlmeier; Jochen Herms; Jürgen Schlegel; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert; Bogdana Suchorska
Journal:  Front Oncol       Date:  2021-03-30       Impact factor: 6.244

5.  Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617.

Authors:  Jolanta Kunikowska; Ingeborga Charzyńska; Radosław Kuliński; Dariusz Pawlak; Michał Maurin; Leszek Królicki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-10       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.